REFERENCES
- Adams J. M., Cory S. 1998. The Bcl-2 protein family: Arbiters of cell survival. Science. 281: 1322–1326. [PUBMED], [INFOTRIEVE]
- Datta S. R., Brunet A., Greenberg M. E.. 1999. Cellular survival: A play in three Akts. Genes and Development. 13: 2905–2927. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hortobagyi G. N.. 1997. Anthracyclines in the treatment of cancer. An overview. Drugs. 54(Suppl 4)1–7. [PUBMED], [INFOTRIEVE]
- Iarussi D., Indolfi P., Casale F., Coppolino P., Tedesco M. A., Di, Tullio M. T.. 2001. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Current Medical Chemistry. 8: 1649–1660
- Johnson S. A., Richardson D. S.. 1998. Anthracyclines in haematology: Pharmacokinetics and clinical studies. Blood Reviews. 12: 52–71. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kaushal G. P., Kaushal V., Hong X., Shah S. V.. 2001. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney International. 60: 1726–1736. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kaushal V., Kaushal G. P., Melkaveri S. N., Mehta P. 2004. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. Joural of Thrombosis and Haemostay. 2: 327–334. [CROSSREF]
- Kotamraju S., Konorev E. A., Joseph J., Kalyanaraman B. 2000. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. Journal of Biological Chemistry. 275: 33585–33592. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kremer L. C., Caron H. N.. 2004. Anthracycline cardiotoxicity in children. New England Journal of Medicine. 351: 120–121. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kwok J. C., Richardson D. R.. 2000. The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity. Redox Report. 5: 317–324. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lorenzo E., Ruiz-Ruiz C., Quesada A. J., Hernandez G., Rodriguez A., Lopez-Rivas A., Redondo J. M.. 2002. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. Journal of Biological Chemistry. 277: 10883–10892. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Olson R. D., Mushlin P. S.. 1990. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB Journal. 4: 3076–3086. [PUBMED], [INFOTRIEVE]
- Safra T. 2003. Cardiac safety of liposomal anthracyclines. Oncologist. 8(Suppl 2)17–24. [PUBMED], [INFOTRIEVE]
- Seymour L., Bramwell V., Moran L. A.. 1999. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prevention and Control. 3: 145–159. [PUBMED], [INFOTRIEVE]
- Speyer J., Wasserheit C. 1998. Strategies for reduction of anthracycline cardiac toxicity. Seminars in Oncology. 25: 525–537. [PUBMED], [INFOTRIEVE]
- Swain S. M., Whaley F. S., Gerber M. C., Weisberg S., York M., Spicer D., Jones S. E., Wadler S., Desai A., Vogel C., Speyer J., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia E., Ewer M. S., Bianchine J. R., Gams R. A.. 1997. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology. 15: 1318–1332. [PUBMED], [INFOTRIEVE]
- Swift L., McHowat J., Sarvazyan N. 2003. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity. Cancer Research. 63: 5992–5998. [PUBMED], [INFOTRIEVE]
- Theodoulou M., Hudis C. 2004. Cardiac profiles of liposomal anthracyclines. Cancer. 100: 2052–2063. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wakabayashi I., Groschner K. 2003. Vascular actions of anthracycline antibiotics. Current Medical Chemistry. 10: 427–436
- Wang S., Konorev E. A., Kotamraju S., Joseph J., Kalivendi S., Kalyanaraman B.. 2004. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H(2)O(2)- and p53-dependent pathways. Journal of Biological Chemistry. 279: 25535–25543. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Weiss R. B.. 1992. The anthracyclines: Will we ever find a better doxorubicin?. Seminars in Oncology. 19: 670–686. [PUBMED], [INFOTRIEVE]
- Wojtacki J., Lewicka-Nowak E., Lesniewski-Kmak K. 2000. Anthracycline-induced cardiotoxicity: Clinical course, risk factors, pathogenesis, detection and prevention—review of the literature. Medical Science Monitor. 6: 411–420. [PUBMED], [INFOTRIEVE]
- Wolf B. B., Schuler M., Echeverri F., Green D. R.. 1999. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor–45/inhibitor of caspase-activated DNase inactivation. Journal of Biological Chemistry. 274: 30651–30656. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wu S., Ko Y. S., Teng M. S., Ko Y. L., Hsu L. A., Hsueh C., Chou Y. Y., Liew C. C., Lee Y. S.. 2002. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and In vivo studies. Journal Molecualr and Cellular Cardiology. 34: 1595–1607. [CROSSREF]
- Zucchi R., Danesi R. 2003. Cardiac toxicity of antineoplastic anthracyclines. Current Medical Chemistry and Anti-Cancer Agents. 3: 151–171